Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2014

View Archived Issues

Potent c-Ros-1 inhibitors discovered at Janssen and NovAliX

Antiangiogenic and antitumor activity described for alpha-tocopherol analogue

Gene identified as a possible novel biomarker for frontotemporal lobar degeneration

ElexoPharm and Merck & Co. report CYP11B2 inhibitors for heart failure and hypertension

U.S. institutions divulge novel GSK-3 inhibitors

Loxo Oncology initiates phase I study of Trk inhibitor for cancer

Covagen initiates first clinical trial of FynomAb bispecific inhibitor

Addition of VX-661 to Kalydeco improves lung function in phase II trial in CF

Promising preclinical results for a novel, live-attenuated plague vaccine

Ruthigen submits IND for anti-infective surgical lavage

Phase III ovarian cancer trial of vintafolide stopped due to lack of efficacy

Camicinal proves well tolerated in diabetic patients with gastroparesis

Bristol-Myers Squibb describes novel FXIa inhibitors

New macrocyclic ketoamides disclosed by Roche

Bristol-Myers Squibb updates pipeline progress of first quarter 2014

NIH gives grant to Scripps Research Institute to develop diagnostics

Cellectar Biosciences' glioma diagnostic obtains FDA orphan drug designation

diaDexus completes validation study for PLAC Test for Lp-PLA2 Activity

Advaxis' immunotherapy product to enter clinic for pediatric bone cancer

ADDF raises funding for trial investigating rasagiline for Alzheimer's disease

Pierre Fabre obtains European approval for Hemangiol

World Asthma Day: Disease control through discovery of new therapeutic targets and models

Acorda receives complete response letter from FDA for Plumiaz

FDA approves Epanova for hypertriglyceridemia

FDA approves IND for Kinex's Oratecan

Alexion achieves regular approval for Soliris in aHUS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...